{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:01:23Z","timestamp":1781478083895,"version":"3.54.1"},"reference-count":43,"publisher":"Becaris Publishing Limited","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            The objective of this study was to compare adverse event (AE) management costs for fruquintinib, regorafenib, trifluridine\/tipiracil (T\/T) and trifluridine\/tipiracil+bevacizumab (T\/T+bev) for patients with metastatic colorectal cancer (mCRC) previously treated with at least two prior lines of therapy from the US commercial and Medicare payer perspectives.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            A cost-consequence model was developed to calculate the per-patient and per-patient-per-month (PPPM) AE costs using rates of grade 3\/4 AEs with incidence \u22655% in clinical trials, event-specific management costs and duration treatment. Anchored comparisons of AE costs were calculated using a difference-in-differences approach with best supportive care (BSC) as a common reference. AE rates and treatment duration were obtained from clinical trials: FRESCO and FRESCO-2 (fruquintinib), RECOURSE (T\/T), CORRECT (regorafenib) and SUNLIGHT (T\/T, T\/T+bev). AE management costs for the commercial and Medicare perspectives were obtained from publicly available sources.\n            <jats:bold>Results:<\/jats:bold>\n            From the commercial perspective, the AE costs (presented as per-patient, PPPM) were: $4015, $1091 for fruquintinib (FRESCO); $4253, $1390 for fruquintinib (FRESCO-2); $17,110, $11,104 for T\/T (RECOURSE); $9851, $4691 for T\/T (SUNLIGHT); $8199, $4823 for regorafenib; and $11,620, $2324 for T\/T+bev. These results were consistent in anchored comparisons: the difference-in-difference for fruquintinib based on FRESCO was -$1929 versus regorafenib and -$11,427 versus T\/T; for fruquintinib based on FRESCO-2 was -$2257 versus regorafenib and -$11,756 versus T\/T. Across all analyses, results were consistent from the Medicare perspective.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Fruquintinib was associated with lower AE management costs compared with regorafenib, T\/T and T\/T+bev for patients with previously treated mCRC. This evidence has direct implications for treatment, formulary and pathways decision-making in this patient population.\n          <\/jats:p>","DOI":"10.57264\/cer-2024-0084","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T13:24:33Z","timestamp":1720617873000},"source":"Crossref","is-referenced-by-count":5,"title":["Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US"],"prefix":"10.57264","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3508-1296","authenticated-orcid":false,"given":"Victoria Federico","family":"Paly","sequence":"first","affiliation":[{"name":"Global Pricing, Value &amp; Access; Global Health Economics &amp; US HEOR \u2013 Oncology,\u00a0Takeda Pharmaceuticals America, Inc., Lexington, MA 02421,\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Dasari","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology,\u00a0MD Anderson Cancer Center, Houston, TX\u00a077030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joleen","family":"Hubbard","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology,\u00a0Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[{"name":"Medical Oncology, Mayo Clinic, Phoenix, AZ\u00a085054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thihan","family":"Padukkavidana","sequence":"additional","affiliation":[{"name":"US Medical Affairs \u2013 Oncology,\u00a0Takeda Pharmaceuticals USA, Inc., Lexington, MA\u00a002421, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9532-546X","authenticated-orcid":false,"given":"Luis","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Global Pricing, Value &amp; Access; Global Health Economics &amp; US HEOR \u2013 Oncology,\u00a0Takeda Pharmaceuticals America, Inc., Lexington, MA 02421,\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_8_3_2","unstructured":"National Cancer Institute. Cancer Stat Facts: Common Cancer Sites. (2023). https:\/\/seer.cancer.gov\/statfacts\/html\/common.html"},{"key":"e_1_3_8_4_2","unstructured":"National Cancer Institute. Cancer Stat Facts: Colorectal Cancer. (2022). https:\/\/seer.cancer.gov\/statfacts\/html\/colorect.html"},{"key":"e_1_3_8_5_2","unstructured":"Centers for Disease Control and Prevention. Basic information about colorectal cancer. (2023). https:\/\/www.cdc.gov\/cancer\/colorectal\/basic_info\/"},{"issue":"4","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3322\/caac.21728","article-title":"Clinical management of metastatic colorectal cancer in the era of precision medicine","volume":"72","author":"Ciardiello F","year":"2022","unstructured":"Ciardiello F, Ciardiello D, Martini G Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J. Clin. 72(4), 372\u2013401 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"e_1_3_8_7_2","unstructured":"Centers for Disease Control and Prevention. United States cancer statistics: data visualizations survival by stage. (2022). https:\/\/gis.cdc.gov\/Cancer\/USCS\/#\/SurvivalbyStage\/"},{"issue":"1","key":"e_1_3_8_8_2","first-page":"2","article-title":"Identifying disease progression in patients with metastatic colorectal cancer: when to initiate third-line therapy","volume":"18","author":"Bekaii-Saab TS","year":"2020","unstructured":"Bekaii-Saab TS. Identifying disease progression in patients with metastatic colorectal cancer: when to initiate third-line therapy. Clin. Adv. Hematol. Oncol. 18(1 Suppl. 2), 2\u20137 (2020).","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"1","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/j.clcc.2018.11.002","article-title":"Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice","volume":"18","author":"Bekaii-Saab T","year":"2019","unstructured":"Bekaii-Saab T, Kim R, Kim TW Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. Clin Colorectal Cancer 18(1), e117\u2013e129 (2019).","journal-title":"Clin Colorectal Cancer"},{"issue":"10207","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker E","year":"2019","unstructured":"Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet 394(10207), 1467\u20131480 (2019).","journal-title":"Lancet"},{"issue":"3","key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3390\/curroncol28030194","article-title":"The Screening and COnsensus based on Practices and Evidence (SCOPE) program \u2013 results of a survey on daily practice patterns for patients with mCRC","volume":"28","author":"Prager G","year":"2021","unstructured":"Prager G, K\u00f6hne CH, O'Connor JM The Screening and COnsensus based on Practices and Evidence (SCOPE) program \u2013 results of a survey on daily practice patterns for patients with mCRC. Curr. Oncol. 28(3), 2097\u20132106 (2021).","journal-title":"Curr. Oncol."},{"issue":"7","key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.7150\/ijms.24453","article-title":"New trends in the therapeutic approach to metastatic colorectal cancer","volume":"15","author":"S\u00e1nchez-Gund\u00edn J","year":"2018","unstructured":"S\u00e1nchez-Gund\u00edn J, Fern\u00e1ndez-Carballido AM, Mart\u00ednez-Valdivieso L, Barreda-Hern\u00e1ndez D, Torres-Su\u00e1rez AI. New trends in the therapeutic approach to metastatic colorectal cancer. Int. J. Med. Sci. 15(7), 659\u2013665 (2018).","journal-title":"Int. J. Med. Sci."},{"issue":"3","key":"e_1_3_8_13_2","first-page":"1","article-title":"Sequencing beyond the second-line setting in metastatic colorectal cancer","volume":"17","author":"Grothey A","year":"2019","unstructured":"Grothey A, Marshall JL, Bekaii-Saab T. Sequencing beyond the second-line setting in metastatic colorectal cancer. Clin. Adv. Hematol. Oncol. 17 Suppl. 7(3), 1\u201319 (2019).","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"1","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes A","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34(1), 10\u201332 (2023).","journal-title":"Ann. Oncol."},{"key":"e_1_3_8_15_2","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Colon Cancer","author":"National Comprehensive Cancer Network","year":"2023","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Colon Cancer. (2023). Version 4.2023."},{"key":"e_1_3_8_16_2","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Rectal Cancer","author":"National Comprehensive Cancer Network","year":"2023","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Rectal Cancer. (2023). Version 6.2023."},{"issue":"6","key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/sj.bjc.6603011","article-title":"FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)","volume":"94","author":"Souglakos J","year":"2006","unstructured":"Souglakos J, Androulakis N, Syrigos K FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br. J. Cancer 94(6), 798\u2013805 (2006).","journal-title":"Br. J. Cancer"},{"issue":"2","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3109\/07357907.2015.1104689","article-title":"XELOX vs. FOLFOX in metastatic colorectal cancer: an updated meta-analysis","volume":"34","author":"Guo Y","year":"2016","unstructured":"Guo Y, Xiong BH, Zhang T, Cheng Y, Ma L. XELOX vs. FOLFOX in metastatic colorectal cancer: an updated meta-analysis. Cancer Invest. 34(2), 94\u2013104 (2016).","journal-title":"Cancer Invest."},{"issue":"9863","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase III trial","volume":"381","author":"Grothey A","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase III trial. Lancet 381(9863), 303\u2013312 (2013).","journal-title":"Lancet"},{"issue":"20","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer RJ","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372(20), 1909\u20131919 (2015).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_8_21_2","unstructured":"STIVARGA (regorafenib) [package insert]. [Bayer HealthCare Pharmaceuticals Inc Whippany NJ (2012). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203085s007lbl.pdf"},{"issue":"6","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase III trial","volume":"16","author":"Li J","year":"2015","unstructured":"Li J, Qin S, Xu R Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase III trial. Lancet Oncol. 16(6), 619\u2013629 (2015).","journal-title":"Lancet Oncol."},{"key":"e_1_3_8_23_2","unstructured":"European Medicines Agency. Lonsurf: summary of product characteristics. (2023). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lonsurf-epar-product-information_en.pdf"},{"key":"e_1_3_8_24_2","unstructured":"LONSURF (trifluridine and tipiracil) [package insert]. [Taiho Pharmaceutical Co Ltd Princeton NJ (September 22 2023). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/207981s012lbl.pdf"},{"issue":"18","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer","volume":"388","author":"Prager GW","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N. Engl. J. Med. 388(18), 1657\u20131667 (2023).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_8_26_2","unstructured":"AVASTIN (bevacizumab) [package insert]. [Genentech Inc San Fransisco CA (2004). https:\/\/www.gene.com\/download\/pdf\/avastin_prescribing.pdf"},{"key":"e_1_3_8_27_2","unstructured":"FRUZAQLA (fruquintinib) [Package insert]. [Takeda Pharmaceuticals America Inc Lexington MA (2023). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217564s000lbl.pdf"},{"issue":"24","key":"e_1_3_8_28_2","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial","volume":"319","author":"Li J","year":"2018","unstructured":"Li J, Qin S, Xu RH Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA 319(24), 2486\u20132496 (2018).","journal-title":"JAMA"},{"issue":"24","key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.2217\/fon-2021-0202","article-title":"FRESCO-2: a global phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer","volume":"17","author":"Dasari A","year":"2021","unstructured":"Dasari A, Sobrero A, Yao J FRESCO-2: a global phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. Future Oncol. 17(24), 3151\u20133162 (2021).","journal-title":"Future Oncol."},{"issue":"11","key":"e_1_3_8_30_2","first-page":"S2","article-title":"Treatment exposure-adjusted event rates (EAERs) for grade 3\/4 AEs associated with emerging and existing systemic therapies for mCRC with at least 2 prior lines of therapy: informing payer and pathway formulary decision making","volume":"26","author":"Howe A","year":"2023","unstructured":"Howe A, Hernandez LG, Paly VF Treatment exposure-adjusted event rates (EAERs) for grade 3\/4 AEs associated with emerging and existing systemic therapies for mCRC with at least 2 prior lines of therapy: informing payer and pathway formulary decision making. Value Health 26(11), S2 (2023).","journal-title":"Value Health"},{"issue":"11","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1007\/s12325-020-01477-w","article-title":"Safety profile and adverse events of special interest for fruquintinib in Chinese Patients with previously treated metastatic colorectal cancer: analysis of the phase III FRESCO trial","volume":"37","author":"Li J","year":"2020","unstructured":"Li J, Guo W, Bai Y Safety profile and adverse events of special interest for fruquintinib in Chinese Patients with previously treated metastatic colorectal cancer: analysis of the phase III FRESCO trial. Adv. Ther. 37(11), 4585\u20134598 (2020).","journal-title":"Adv. Ther."},{"key":"e_1_3_8_32_2","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.2147\/OTT.S307273","article-title":"Subgroup analysis by liver metastasis in the Fresco trial comparing fruquintinib versus placebo plus best supportive care in chinese patients with metastatic colorectal cancer","volume":"14","author":"Qin S","year":"2021","unstructured":"Qin S, Xu RH, Shen L Subgroup analysis by liver metastasis in the Fresco trial comparing fruquintinib versus placebo plus best supportive care in chinese patients with metastatic colorectal cancer. Onco. Targets Ther. 14, 4439\u20134450 (2021).","journal-title":"Onco. Targets Ther."},{"issue":"11","key":"e_1_3_8_33_2","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2217\/fon-2020-0875","article-title":"Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, phase III trial","volume":"17","author":"Xu R","year":"2021","unstructured":"Xu R, Qin S, Guo W Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, phase III trial. Future Oncol. 17(11), 1339\u20131350 (2021).","journal-title":"Future Oncol."},{"key":"e_1_3_8_34_2","doi-asserted-by":"crossref","first-page":"S1391","DOI":"10.1016\/j.annonc.2022.08.021","article-title":"LBA25 FRESCO-2: a global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer","volume":"33","author":"Dasari NA","year":"2022","unstructured":"Dasari NA, Lonardi S, Garcia-Carbonero R LBA25 FRESCO-2: a global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer. Ann. Oncol. 33, S1391\u2013S1392 (2022).","journal-title":"Ann. Oncol."},{"issue":"2","key":"e_1_3_8_35_2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12094-016-1528-7","article-title":"Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase III RECOURSE trial","volume":"19","author":"Longo-Mu\u00f1oz F","year":"2017","unstructured":"Longo-Mu\u00f1oz F, Argiles G, Tabernero J Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase III RECOURSE trial. Clin. Transl. Oncol. 19(2), 227\u2013235 (2017).","journal-title":"Clin. Transl. Oncol."},{"issue":"4","key":"e_1_3_8_36_2","doi-asserted-by":"crossref","first-page":"e000752","DOI":"10.1136\/esmoopen-2020-000752","article-title":"Effect of trifluridine\/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis","volume":"5","author":"Tabernero J","year":"2020","unstructured":"Tabernero J, Argiles G, Sobrero AF Effect of trifluridine\/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis. ESMO Open 5(4), e000752 (2020).","journal-title":"ESMO Open"},{"key":"e_1_3_8_37_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2017.10.009","article-title":"The subgroups of the phase III RECOURSE trial of trifluridine\/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer","volume":"90","author":"Van Cutsem E","year":"2018","unstructured":"Van Cutsem E, Mayer RJ, Laurent S The subgroups of the phase III RECOURSE trial of trifluridine\/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur. J. Cancer 90, 63\u201372 (2018).","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"e_1_3_8_38_2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.annonc.2019.10.005","article-title":"Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine\/tipiracil in the RECOURSE and J003 trials","volume":"31","author":"Yoshino T","year":"2020","unstructured":"Yoshino T, Cleary JM, Van Cutsem E Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine\/tipiracil in the RECOURSE and J003 trials. Ann. Oncol. 31(1), 88\u201395 (2020).","journal-title":"Ann. Oncol."},{"issue":"4","key":"e_1_3_8_39_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1200\/JCO.2023.41.4_suppl.4","article-title":"Trifluridine\/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: the phase III randomized SUNLIGHT study","volume":"41","author":"Tabernero J","year":"2023","unstructured":"Tabernero J, Prager GW, Fakih M Trifluridine\/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: the phase III randomized SUNLIGHT study. J. Clin. Oncol. 41(Suppl. 4), 4\u20134 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"10395","key":"e_1_3_8_40_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase III study","volume":"402","author":"Dasari A","year":"2023","unstructured":"Dasari A, Lonardi S, Garcia-Carbonero R Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase III study. Lancet 402(10395), 41\u201353 (2023).","journal-title":"Lancet"},{"key":"e_1_3_8_41_2","unstructured":"US Centers for Medicare & Medicaid Services. FY 2023 IPPS Final Rule Home Page. (2023). https:\/\/www.cms.gov\/medicare\/payment\/prospective-payment-systems\/acute-inpatient-pps\/fy-2023-ipps-final-rule-home-page"},{"key":"e_1_3_8_42_2","unstructured":"Agency for Healthcare Research and Quality. Clinical Classifications Software Refined (CCSR) for ICD-10-CM Diagnoses. Healthcare Cost and Utilization Project (HCUP). (2022). http:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/ccsr\/dxccsr.jsp"},{"key":"e_1_3_8_43_2","unstructured":"Bureau of Labor Statistics UDoL. Consumer Price Index. (2023). https:\/\/www.bls.gov\/news.release\/archives\/cpi_01182017.pdf"},{"key":"e_1_3_8_44_2","unstructured":"Centers for Medicare and Medicaid Services. Medicare Physician Fee Schedule Look-Up Tool: 2023 National Payment Amount by HCPCS Code. (2023). https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search\/overview"},{"key":"e_1_3_8_45_2","unstructured":"Practice Management Information Corporation. Medical Fees Directory 2023 - eBook. Usual Customary and Reasonable (UCR) Fees. (2023)."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T10:26:12Z","timestamp":1721903172000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.57264\/cer-2024-0084"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0084","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]},"article-number":"e240084"}}